5 Comments

CHAPTER 12 CELL CYCLE REGULATION AND HEMATOLOGICAL DISORDERS

CHAPTER 12 CELL CYCLE REGULATION AND HEMATOLOGICAL DISORDERS
Williams Hematology

CHAPTER 12 CELL CYCLE REGULATION AND HEMATOLOGICAL DISORDERS

MATHIAS SCHMID
DENNIS A. CARSON

Introduction

Cyclins and Cyclin-Dependent Kinases

Substrates and Inhibitors of Cyclin-Dependent Kinases
Oncogenes
Tumor Suppressor Genes
Chapter References

Complex feedback pathways regulate the passage of cells through the G1, S, G2, and M phases of the growth cycle. Two key checkpoints control the commitment of cells to replicate DNA synthesis and to mitosis. Many oncogenes and tumor suppressor genes promote malignant change by stimulating cell cycle entry, or disrupting the checkpoint response to DNA damage. This chapter presents the pathways that regulate cell replication and tabulates the various oncogenes that have been shown to be involved in hematologic and some other malignancies.

Acronyms and abbreviations that appear in this chapter include: CDI, cyclin-dependent kinase inhibitors; CDK, cyclin-dependent kinases; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; HIV, human immunodeficiency virus 1; MPF, M-phase promoting factor; RAR-a, retinoic acid receptor-a; rb, retinoblastoma; rPTK, receptor protein-tyrosine kinases; SPF, S-phase promoting factor; TAR, transactivation response element.

INTRODUCTION
Cell mitosis is the final step of a defined program—the cell cycle—which can be separated into four phases: the G1-, S-, G2-, and M phases (Fig. 12-1). A number of surveillance systems (checkpoints) control the cell cycle and interrupt its progression when DNA damage occurs or when the cells have failed to complete a necessary event.1 These checkpoints have been given an empirical definition: When the occurrence of an event B is dependent on the completion of a prior event A, the dependence is due to a checkpoint if a loss-of-function mutation can be found that relieves the dependence.1 Three major cell cycle checkpoints have been discovered: the DNA damage checkpoint, the spindle checkpoint, and the spindle pole body duplication checkpoint.2,3 and 4

FIGURE 12-1 Cell cycle regulation in mammalian cells.

The functional consequence of cell cycle checkpoint failure is usually death by apoptosis. However, small numbers of genetically altered cells may survive. Cells with defective checkpoints have an advantage when selection favors multiple genetic changes. Cancer cells are often missing one or more checkpoints, which facilitates a greater rate of genomic evolution.5
Most of the basic principles of cell cycle regulation were worked out in yeast, but the underlying principles are equally applicable to the mammalian cell cycle. One must understand basic cell cycle regulation in order to understand the mechanisms that lead to hematological malignancies and the importance of tumor suppressor genes and oncogenes.
CYCLINS AND CYCLIN-DEPENDENT KINASES (TABLE 12-1)

TABLE 12-1 CDKs, ASSOCIATED CYCLINS, AND THE STAGE OF THE CELL CYCLE WHERE THEY ACT

Early experiments on the control of mitosis in human cells provided evidence for the existence of factors called M-phase and S-phase promoting factors (MPF, SPF).6 The key element of SPF was thought to be cdc2. Experiments performed in Xenopus eggs showed that cdc2 is an M-phase-specific histone H1 kinase7 but is just one subunit of a regulatory complex. A second component is cyclin B, which is synthesized in interphase and degraded in mitosis. At least eight members of the mammalian cyclin family have been cloned to date (cyclins A-H). These cyclins all interact with a group of cdc2-related kinases called cyclin-dependent kinases (cdk).8,9 The cyclin/cdk complex is the mammalian counterpart of the cdc2/cdc13 complex in yeast. Phosphorylation of tyrosine 15 is the key event in regulating human cdc2 activity. Threonine 14 also is phosphorylated in G2 phase. Both phosphorylation sites are required for mitotic initiation. Cdc2 interacts with cyclin B in mitosis, whereas the cdc2/cyclin A complex is formed before mitosis and probably is required for progression through late G2 phase10 Thus, cyclins A and B are also called the mitotic cyclins, since they are upregulated in late G2 or G2/M and undergo proteolysis in M phase.
The exit from mitosis is characterized by the abrupt ubiquitination and subsequent degradation of cyclin B. Cells with a defective cyclin B degradation mechanism or without mitotic cyclin B easily become aneuploid. The exact role of the other mitotic cyclin, cyclin A, is still unclear. There is evidence that it both acts at the G2/M transition and binds cdk2 in S phase. Overexpression of cyclin A in G1 phase leads to an accelerated entry into S phase.11 Since cdc2 is able to interact with mitotic and G1 cyclins, it seems likely that one protein kinase potentially can fulfill several different functions in the cell cycle at various checkpoints. The redundancy of cyclin functions makes it difficult to ascertain the exact function of each protein in all cell types.
There are several cdc2-related protein kinases in humans that interact with the corresponding cyclins. Originally, three cdc2-related proteins were isolated which were able to replace deficient cdc28 function in budding yeast: cdk1, cdk2, and cdk3.12,13,14 and 15 Another group of cdks that bind to cyclin D (a G1 cyclin) have been named cdk4,16 cdk5,17 and cdk6.18 Cdk4 has been in the focus of tumor suppressor gene reseach for the last several years, since it complexes with cyclin D1. This complex is an important element in the p16INK4A-retinoblastoma (rb) gene pathway, which is commonly disrupted in cancer (see below). Three other cyclin-dependent kinases have been partially characterized: cdk7 (p40MO15) interacts with cyclin H and is responsible for phosphorylating pcdc2 on threonine 161.19,20 and 21 Cdk8 interacts with cyclin C and is associated with RNA polymerase II.22,23 and 24 Cdk9 binds cyclin T1 and displays a tissue-specific expression pattern.25,26 and 27 The fact that cdk9/cyclin T1 specifically interacts with the tat element of the human immunodeficiency virus 1 (HIV-1) links this cyclin-dependent kinase directly to the replication pathway of HIV, and circumstantially to HIV-1 related malignancies (e.g., Kaposi sarcoma).28,29 and 30
All cyclins share an approximately 150 amino acid region, called the cyclin box, which interacts with the cdks.31 The G1 cyclins (C, D, and E) and the mitotic cyclins (A and B)32 form distinct categories, although cyclin H and the type T cyclins (T1, T2a, and T2b) fall outside these two major groups.
Cyclin A binds and activates cdk2 mainly in S phase. However, microinjection of anticyclin A antibodies into cells causes cell cycle arrest just before S phase.10 The integration of the hepatitis B virus into the cellular genome is accompanied by the formation of a chimeric cyclin A, lacking the cyclin destruction box, and with a prolonged half-life.33 This observation, together with the finding that overexpression of cyclin A leads to accelerated S-phase entry, suggests that cyclin A is involved in transformation.11 The other cyclin that interacts with cdk2, cyclin E, may control the progression from G1 to S phase, but the exact timepoint when cdk2 “switches” from cyclin E to cyclin A binding is unknown. Cdk2/cyclin E activity peaks during late G1 phase, and declines in early S phase.34 Cells overexpressing cyclin E progress much faster through G1 into S phase, but the time required for DNA synthesis remains normal.35 Cyclin E levels also are regulated by environmental factors, including TGF-b and irradiation. These effects are, in part, mediated by small proteins, the cyclin-dependent kinase inhibitors (CDI). In addition to its role at the G1/S boundary, cyclin A acts in late G2 phase, where it complexes with cdk1. It has been suggested that this interaction might be necessary for the reorganization of the cytoskeleton prior to mitosis.36
The B-type cyclins associate with cdk1 and cdk2 to form the classical mitotic cyclin/cdk complexes.37 Cyclin B is synthesized in S phase and accumulates together with cdk2. Ubiquitin mediates the degradation of cyclin B, allowing the cell to exit from mitosis. The cyclin B/cdk2 checkpoint is very often defective in malignant cells, leading to uncontrolled M-phase entry and aneuploidy. The cellular localization of the cdk1-cyclin B complexes also is strictly cell-cycle–dependent. Although the complexes accumulate in the cytoplasm during G2 and S phase, they move to the nucleus in mitosis and bind to the mitotic spindle.38,39,40 and 41
The three different cyclin D molecules (D1, D2, and D3) function mainly in late G1 phase, where they bind cdk4 and cdk6. These complexes phosphorylate rb, restraining its inhibitory effects on E2F, and related transcription factors. Cyclin D1 is the major D cyclin in most cell types. All three cyclin D molecules act in late G phase, just before entry into S phase. Forced overexpression of cyclin D1 shortens the G1 phase. Many tumors have high cyclin D1 levels without amplification or mutation of the cyclin D1 structural gene. Instead, cycle D levels may be regulated by a feedback loop dependent on rb. Alterations of the retinoblastoma gene in cancer may secondarily cause upregulation of cyclin D transcription.
The most recently identified member of the cdk-family, cdk9, partners with cyclin T, an 87-kDa cyclin C type protein with three subunits.25 The cdk9/cyclin T complex is an essential component of the P-TEFb human transcription elongation factor.26 P-TEFb can hyperphosphorylate the C-terminal domain of RNA polymerase II, similar to the cyclin H/cdk7/MAT1 complex.28 In addition, P-TEFb forms a complex with the HIV tat protein that binds the transactivation response element (TAR). The modification of RNA polymerase II by cdk9/cyclin T facilitates the efficient multiplication of the viral genome.42,43 The fact that the cyclin T1/cdk9 complex is upregulated during T-cell activation enables the HIV to utilize this complex for replication.44 Another binding partner of cdk9 is a tumor necrosis factor signal transducer molecule, TRAF2.45
SUBSTRATES AND INHIBITORS OF CYCLIN-DEPENDENT KINASES
Many cyclin-cdk substrates have been identified by immunoprecipitation or two-hybrid assays, but only a few of them are thought to exert a direct function in cell cycle control. In G1 phase, the most important substrate of the cdk4-cyclin D and cdk6-cyclin D complexes is rb (Fig. 12-2). In its hypophosphorylated state, rb binds to and inhibits a class of transcription factors, of which the best characterized is the E2F transcription factor. Hyperphosphorylation causes rb to detach from its binding site, permitting transcriptional activation of genes necessary for DNA synthesis and cell division. This phosphorylation of rb is regulated in a cell-cycle–dependent manner.46,47 and 48 Interference with rb function impairs G1 checkpoint regulation, fosters unrestrained cell growth, and is a nearly universal characteristic of malignancy. Causes of reduced rb activity include changes in the structural gene, the sequestration and inactivation of the protein by viral oncogene products, and hyperphosphorylation of rb due to increased cdk4 and cyclin D activity or to deletion of the gene for the p16INK4A inhibitor of cdk4. Deletions, mutations, and translocations of rb are common in various malignancies, while homozygous deletions of the p16INK4A gene are even more frequent. Many different transforming viruses, such as papilloma virus and simian virus 40, produce proteins that interact with rb. Both cyclin D1/cdk4 and cyclin D1(D2, D3)/cdk6 complexes are able to phosphorylate the rb.49,50 The timepoint of rb-phosphorylation correlates strongly with the appearance of the cyclin D1/cdk4 complex. The link between rb and cyclin D is supported by the observation that loss of rb function leads to a decrease in the cellular cyclin D level.51,52 However, cyclin D may not be the only cyclin that is involved in the rb regulatory pathway.53,54 Ectopic expression of both cyclin A and cyclin E restores rb hyperphosphorylation and causes cell cycle arrest in cancer cell lines. Perhaps the cdk2-cyclin A complex contributes to additional phosphorylation of rb, whereas cdk2/cyclin E prolongs the phosphorylation time.53

FIGURE 12-2 Interactions between cyclin-dependent kinase inhibitors (p16, p14, p21), p53, and the retinoblastoma protein (rb).

Two rb-related proteins, p107 and p130, also form complexes with the transcription factor E2F,52,55,56 bind to the region of the adenovirus E1A protein required for transformation, and are able to induce G1 arrest when they are overexpressed in human malignant cell lines.57,58 and 59 Unlike the rb, the p107 and p130 proteins contain a so-called spacer region that interacts with cdk2/cyclin A and cdk2/cyclin E,60,61 although it seems to be unlikely that these two complexes regulate the activity of p107 and p130.53 Instead, p107 may bind and inactivate the cyclin A and cyclin E complexes. Thus, p107 may regulate the cell cycle by several different mechanisms. Since both p107 and p130 are regulated through phosphorylation, efficient cell cycle entry is accompanied by phosphorylation of all the rb-related proteins.
The cyclin-dependent kinases themselves are also controlled by several different mechanisms. Besides their regulation by phosphorylation, specific protein inhibitors of enzyme activity have been identified.62,63 The cyclin-dependent kinase inhibitors cause cells to arrest in G1 phase, followed by differentiation and/or senescence. The first cyclin-dependent kinase inhibitor identified was p21cip1.64 It binds to several cyclin/cdk complexes including cyclin A/cdk2, cyclin D/cdk4, and cyclin E/cdk2 (Fig. 12-2).46,47 and 48,65,66 and 67 Several different cell cycle regulatory pathways involve p21cip1. This molecule has a p53 binding site in its promoter, and an increase in p53 levels results in transcriptional activation of p21cip1, slowing down cell-cycle progression. The p21cip1 cyclin-dependent kinase inhibitor also plays a role in cellular differentiation in myoblasts.68 Other members of the p21cip1 family of cyclin-dependent kinase inhibitors include p27kip1 and p57kip2.49,50 High-level expression of p27kip2 leads to a cell cycle block in G1 phase after treatment of cells with TGF-b. One major difference between p21cip1 and p27kip1 is that the former binds predominantly to cdk2 whereas the latter binds cdk4.
The second group of cyclin-dependent kinase inhibitors belong to the inhibitor of kinase 4 (INK4) family and include p15INK4B, p16INK4A, p18, and p19.51,52,53,54,55 and 56 They all bind and inhibit the cyclin D1/cdk4 and/or cyclin D1/cdk6 complex, which regulates cell-cycle progression via the rb.51,54,55 TGF-b also is a potent inducer of p15INK4B.55 p16INK4A is probably the most important cyclin-dependent kinase inhibitor, since the p16INK4A gene is inactivated by several mechanisms in many different human cancers (see below).
Cyclin concentrations are regulated by ubiquitination and subsequent proteolysis. The formation of ubiquitin/protein complexes requires a ubiquitin-activating enzyme, a ubiquitin-conjugating enzyme, and a so-called specificity factor, which permits substrate recognition. Polyubiquitinated proteins are degraded by the 26S proteasome complex. There are two major ubiquitination systems in the cell, designated SCF and APC.57,58,59 and 60 SCF is named for three of its core components, Skp1, Cdc53, and an F-box containing protein. Important examples of SCF substrates are: Cln1, Sic1, Wee1 Cdc6/Cdc18, E2F, cyclin D1, cyclin E, p21cip1, p27kip1, and p57kip2.61 The APC complex regulates sister chromosome separation as well as exit from telophase into G1. APC substrates include cyclins A and B, Cdc20, Cdc5, Pds1, and Ase, a spindle protein.69 The exact mechanisms that precisely time substrate destruction are not fully understood. However, ubiquitination of distinct cell cycle proteins clearly plays an important role in cell-cycle regulation.
ONCOGENES (TABLE 12-2)

TABLE 12-2 ONCOGENES, THEIR CHROMOSOMAL LOCALIZATION AND LINKAGE TO HUMAN MALIGNANCIES

The complicated cell-cycle network has its parallel in the several different oncogenes and tumor suppressor genes that influence carcinogenesis and tumor progression. The products of oncogenes, the onco-proteins, lead to or faciltitate the transformation of a normal into a malignant cell. Oncogenes can be carried into the cell by viruses or they can arise from mutations in normal cellular genes. Oncoproteins can interact directly with cell-cycle regulatory proteins or control their activity by phosphorylation and dephosphorylation. Not all mutations in oncogenes lead to an altered function of the resulting product. The nomenclature in the oncogene tumor suppressor gene field is not always clear. As a general guideline, if a mutation causes a functional loss of the gene product, and the recessive loss of function leads directly to uncontrolled cell division, the underlying gene can be named a tumor suppressor gene. On the other hand, if the mutation leads to an altered gene product that interacts abnormally with other proteins to influence the cell cycle, this gene is an oncogene, acting in a dominant fashion. Mutations are found in both oncogenes and tumor suppressor genes. Translocations are typical of oncogenes, whereas homozygous deletions and hypermethylation of CpG-nucleotide repeats are characteristic features of tumor suppressor genes.
Probably more than 100 oncogenes and oncogene candidates have been described in the literature. The number of tumor suppressor genes is not much smaller. They are both involved in the pathogenesis and development of all kinds of tumors, especially the hematologic malignancies.
Mutant-activated receptor protein-tyrosine kinases (rPTK) comprise a family of very well characterized oncogenes. The constitutive activation of rPTK usually is achieved by mutations that lead to the dimerization and activation of their cytoplasmic cytalytic domains.70 Prominent examples include Neu/ERbB and CSF-1 oncogenes. NeuERbB2 is frequently mutated in breast cancer as well as in brain tumors.71,72 and 73 Another possible cause of rPTK dimerization is chromosomal translocations that create chimeric proteins. In the t(2;5) translocation, found in several anaplastic large cell lymphomas, N-terminal nucleophosmin sequences on the long arm of chromosome 5 are fused to the cytoplasmic domain of the Alk protein on chromosome 2.74,75 The characteristic translocation of chronic myelomonocytic leukemia (CMML), t(5;12), fuses sequences from the transcription factor Tel to the cytoplasmic domain of the platelet-derived growth factor-b receptor (PDGF-a rPTK), resulting in the formation of a Tel/PDGFbR fusion protein and the constitutive activation of the PTK.76 The chromosomal area surrounding the Tel gene is a fragile site, since the Tel gene is involved in several other translocations in human acute leukemias [e.g., t(12;9)]. The t(9;21) translocation, also called the Philadelphia chromosome, is a characteristic feature of chronic myelogenous leukemia (CML) and, less frequently, of other chronic myeloproliferative syndromes. It fuses the c-abl and bcl-2 oncogenes. Amplification of the fusion sequence is frequently used to detect minimal residual disease in patients under therapy with interferon-a and after bone marrow- or stem cell transplantation.77,78 and 79 Other oncogenes that belong to this family are Ret (mutations in Ret cause multiple endocrine neoplasia type 2A and type 2B)80, and c-Cbl, the homolog of the C. elegans gene Sli1.81
For several years, oncogene research focused on growth factor receptors because of the possibilities for therapeutic intervention. For example, the murine myeloproliferative leukemia virus protein (v-Mpl) is actually a mutant form of the human thrombopoietin receptor (c-Mpl). V-Mpl has part of the viral Env protein fused to the C-terminal end of c-Mpl and is activated through dimerization. This blocks normal differentiation and leads to uncontrolled cell growth. It has been suggested that one of the TGF-b receptors also is involved in oncogenesis, since mutations have been found frequently in colon cancer. TGF-b receptor signalling acts through the Smad family of transcription factors.
Two very important oncogene families encode the ras and rho family proteins. Ras itself is a G-protein, and activating mutations in H-Ras, K-Ras, and N-Ras have been found in nearly all kinds of human cancers. Several different Ras mutations are able to transform normal cells in tissue culture.82,83,84 and 85 Mutations in many different Ras family members have been identified in cancer (e.g., Raf1, p110 PI3 kinase, Rin1, Mekk1), but the exact downstream signalling effects of each mutation are still unclear. The Ras and the Rho family of oncoproteins are linked by a small G-protein called Rac, which is required for transformation by Ras.86,87 and 88 The Rho family of small G-proteins also regulates actin stress fiber formation.89 The regular formation of actin filaments is required for G1/S-phase entry. Thus, alterations in the Rho pathway may lead to premature entry into S phase by interference with cytoskeletal organization. The NF2 tumor suppressor gene also encodes a cytoskeletal protein.90 The two oncogenes BRCA1 and BRCA2 are frequently mutated in affected families with breast cancer.91,92 and 93 Their oncogenic activity might be associated with the transactivating property of the C-terminal ends of the genes, since mutations in this area inactivate this activity.94
Mitogen-activated protease kinases are potential downstream effectors of the Ras pathway.95,96 The three different MAP kinase cascades are the ERK-, JNK/SAPK-, and the p38 pathways. The MAP kinase pathways consist of three types of kinases in a series, MAPK, MAPKK, and MAPKKK. The MAP kinase cascades all transmit responses from several different surface receptors to the nucleus.97 Activation of the Ras-ERK pathway causes cyclin D overexpression and therefore promotes G1-phase progression.98
Several oncogene proteins are localized in the nucleus and include transcription factors and chromatin regulatory proteins. A characteristic feature of acute promyelocytic leukemia (APL) is a t(15;17) translocation that fuses the Pml protein to the retinoic acid receptor-a (RAR-a). The chimeric protein disrupts a nuclear structure called PODS in a retinoic acid reversible fashion.99,100 The detection and molecular characterization of the t(15;17) translocation, together with the development of retinoic acid therapy, was a direct result of oncogene research.101,102 and 103 A variant of this chromosomal translocation results in a fusion protein between RAR-a and the promyelocytic leukemia Kruppel-like zink finger (PLZF) protein, which is observed in a subset of patients with APL.104
Recent experiments on oncoproteins have focused on apoptosis, the lethal response of a cell to either DNA damage or to signaling through cell surface “death” receptors. Key regulators of apoptosis induced by DNA damage are the multiple members of the bcl family of proteins, which include bcl, bcl-XL, bax, and bad. Bcl-2 is involved in the t(14;18) chromosomal translocation, which is found in many leukemias and lymphomas of B-cell origin.105,106 and 107 The disruption of these loci increases expression of bcl, and results in the uncontrolled accumulation of malignant B cells, due to an impaired balance between growth and apoptosis.108,109 and 110 Apoptosis also is controlled by certain tumor suppressor genes, such as p53, that influence the cellular response to DNA damage. The nuclear histone deacetylase complex, which regulates the structural conformation of DNA and therefore the activation of several genes, is targeted by Eto, the fusion partner of the acute myelogenous leukemia AML1 gene. The t(8;21) translocation that occurs in acute myelogenous leukemia allows the formation of a stable complex between the histone deacetylase complex and Eto, with resultant leukemogenesis.111,112 and 113 Other ongogenes that target the histone deacetylase complex are PLZF, PLZF-RAR-a, and BCL-6.114,115 and 116 This implies that specific histone deacetylase inhibitors might be useful drugs in the treatment of myeloid leukemias. Recent reports provide evidence for this hypothesis (see below) and underline the important role of epigenetic phenomena in hematologic malignancies.
TUMOR SUPPRESSOR GENES (TABLE 12-3)

TABLE 12-3 CHARACTERIZATION OF HUMAN TUMOR SUPPRESSOR GENES

Almost every cancer harbors one or more abnormalities of tumor suppressor genes. These include mutations, translocations, and deletions. In addition, at least two epigenetic mechanisms, the hypermethylation of CpG islands in the promoter and the abberant acetylation of histones (especially histone H4), can silence tumor suppressor genes in a variety of human cancer cell lines and primary tumors.
It is remarkable that the products of the three most important tumor suppressor genes (rb, p53, and p16INK4A) are interconnected biochemically. The retinoblastoma gene maps to chromosome 13q14 and has several downstream effectors, among which the transcription factor E2F is the best characterized.117 The retinoblastoma gene family consists of three closely related proteins, rb, p107, and p130. All three proteins are able to interact with several E2F family members. Transcriptional activation and repression are mediated via complexes consisting of rb family members, E2F family members, and so-called DP proteins.118 Besides its role in cell cycle control, rb can modulate RNA polymerase activity, thus linking cell-cycle progression to transcriptional regulation. More than 30 separate cellular proteins have been identified that bind to rb. These proteins can be divided into different groups, including transcription factors, growth factors, protein kinases, protein phosphatases and nuclear matrix proteins. Mutations of rb are frequent in leukemias, soft tissue sarcomas, breast, esophagus, prostate, and renal carcinomas.119 Several viral or oncoproteins can bind to and inactivate rb.120
The p53 gene has been called a “guardian” of the genome because it transmits signals arising from various forms of DNA damage, leading to cell cycle arrest or apoptosis. The major regulator of p53 expression is MDM2. The MDM2 protein inhibits p53 transcription and stimulates p53 degradation.121,122 The MDM2 binding region includes several phosphorylation sites, although the exact mechanism by which MDM2 regulates p53 degradation is still not clear.121,122,123 and 124 The recently discovered p14ARF tumor suppressor gene, which is encoded within the p16INK4A locus by alternate splicing, controls MDM2 activity.125,126 The p14ARF gene shares exons 2 and 3 with p16INK4A but has a distinct exon 1. The discovery that two important tumor suppressor genes are encoded by the same chromosomal locus and share several exons was unexpected and is unique in human biology. The p16INK4A gene function depends on p53, since overexpression of p16INK4A causes cell cycle arrest in p53-wild type cells but not in p53-dependent cells.127 The transcription of p16INK4A is regulated by E2F, which is under the control of rb.128 This indicates the existence of yet another feedback loop, which links the rb pathway to p53.129 The Ras protein is another recently identified p16INK4A factor involved in MDM2-p53-p21-rb regulation.130,131 and 132
Abnormalities of p53 are found in slightly more than 50 percent of all human tumors and, surprisingly, even in some normal cells. It is unclear if these “normal” cells represent a pool of premalignant cells in an otherwise healthy body or if p53 changes are just one step in multistage tumorigenesis. Recently, a human p53 homologue, p73, has been described, which has DNA binding, transactivation, and oligomerization domains similar to p53. The p73 gene has been localized to chromosome 1p36, a common region of cytogenetic changes in cancer. If p73 is overexpressed, the pzl cyclin-dependent kinase inhibitor, a downstream element in the p53 pathway, is also upregulated.133 The p73 protein also can bind p53, inhibiting its transcriptional regulatory activity.134 Although p53 mutations are found in many cancers, p73 mutations apparently are much more rare. However, the p73 gene is inactivated by hypermethylation of CpG-islands in its promoter region in both leukemias and lymphomas.135 This finding supports the hypothesis that p73 is a tumor suppressor gene on chromosome 1p.
Homozygous deletions of the p16INK4A/p14ARF gene locus on human chromosome 9p21 have been detected in gliomas,56,136,137 primary cancers of the lung,56,138,139 bladder,140,141 and 142 head and neck,143,144 and 145 as well as in acute T-cell leukemias146,147 and 148 and mesotheliomas.149 Since inherited mutations of p16INK4A exon 2 may interfere with its expression and/or function, without causing an amino acid change in p14ARF, it is clear that p16INK4A inactivation alone is an important step in the evolution of malignant disease. However, in established tumor cell lines, nearly all chromosome 9p21 deletions disable the entire p16INK4A/p14ARF locus. The p15INK4B gene, also located on chromosome 9p21, about 20 kDa centromeric of p16INK4A, is deleted somewhat less frequently. Analyses of primary tumors, however, have shown that not all 9p21 deletions encompass these three tumor suppressor genes. One mechanism for disruption of the p15INK4B/p14ARF/p16INKA region in T-cell leukemias may be the action of an illegitimate V(D)J recombinase.150
Hypermethylation of CpG islands in the promoter areas of both p16INK4A and p15INK4B are frequently found in hematological malignancies.151,152,153,154 and 155 The availability of demethylating agents such as 5-aza-2′-deoxycytidine (decitabine) makes this phenomenon interesting for chemotherapy.156,157 Decitabine has been used to treat patients suffering from different hematological malignancies and was reported to have activity in advanced myelodysplastic syndrome, accompanied by demethylation of the p16INK4A promoter.158,159,160 and 161 Transcriptional regulation by methylation is mediated by a multiprotein complex consisting of a MeCP2, a methylcytosine-binding protein with a transcriptional repressor domain that binds the corepressor mSin3A, which is itself one element of a multiprotein complex that includes histone deacetylase HDAC1 and HDAC2.162,163 Therefore, reexpression of silenced genes can be achieved by demethylating DNA or by destabilizing histone deacetylases. A mammalian protein with specific demethylase activity for methylated CpG islands has been detected recently164 indicating that gene silencing by epigenetic mechanisms is highly regulated in vertebrate organisms. Histone deacetylase inhibitors and demethylating agents act synergistically to induce genes silenced in cancer by hypermethylation.165 Based on these findings, the MeCP2/SIN3A/HDAC1/2 complex may represent a new target for antineoplastic therapy.
In addition to the three major tumor suppressor gene pathways described above, several others have been identified. It is noteworthy that many different tumor suppressors can be inactivated by hypermethylation.
CHAPTER REFERENCES

1.
Hartwell LH, Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science 246:629, 1989.

2.
Elledge SJ: Cell cycle checkpoints: preventing an identity crisis. Science 274:1664, 1996.

3.
Russell P: Checkpoints on the road to mitosis. Trends Biochem Sci 23:399, 1998.

4.
Murray AW: The genetics of cell cycle checkpoints. Curr Opin Genet Dev 5:5, 1995.

5.
Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821, 1994.

6.
Rao PN, Johnson RT: Mammalian cell fusion: studies on the regulation of DNA synthesis and mitosis. Nature 225:159, 1970.

7.
Lohka MJ, Hayes MK, Maller JL: Purification of maturation-promoting factor, an intracellular regulator of early mitotic events. Proc Natl Acad Sci U S A 85:3009, 1988.

8.
Sherr CJ: Mammalian G1 cyclins. Cell 73:1059, 1993.

9.
Pines J: Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem Sci 18:195, 1993.

10.
Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G: Cyclin A is required at two points in the human cell cycle. Embo J 11:961, 1992.

11.
Resnitzky D, Hengst L, Reed SI: Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol 15:4347, 1995.

12.
Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E, Tsai LH: A family of human cdc2-related protein kinases. Embo J 11:2909, 1992.

13.
Ninomiya-Tsuji J, Nomoto S, Yasuda H, Reed SI, Matsumoto K: Cloning of a human cDNA encoding a CDC2-related kinase by complementation of a budding yeast cdc28 mutation. Proc Natl Acad Sci U S A 88:9006, 1991.

14.
Solomon MJ: Activation of the various cyclin/cdc2 protein kinases. Curr Opin Cell Biol 5:180, 1993.

15.
Lew J, Wang JH: Neuronal cdc2-like kinase. Trends Biochem Sci 20:33, 1995.

16.
Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, Sherr CJ: Identification and properties of an atypical catalytic subunit (p34PSK- J3/cdk4) for mammalian D type G1 cyclins. Cell 71:323, 1992.

17.
Xiong Y, Zhang H, Beach D: D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505, 1992.

18.
Meyerson M, Harlow E: Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14:2077, 1994.

19.
Fesquet D, Labbe JC, Derancourt J, et al: The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. Embo J 12:3111, 1993.

20.
Fisher RP, Morgan DO: A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 78:713, 1994.

21.
Makela TP, Tassan JP, Nigg EA, Frutiger S, Hughes GJ, Weinberg RA: A cyclin associated with the CDK-activating kinase MO15. Nature 371:254, 1994.

22.
Tassan JP, Jaquenoud M, Leopold P, Schultz SJ, Nigg EA: Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. Proc Natl Acad Sci U S A 92:8871, 1995.

23.
Leclerc V, Tassan JP, O’Farrell PH, Nigg EA, Leopold P: Drosophila Cdk8, a kinase partner of cyclin C that interacts with the large subunit of RNA polymerase II. Mol Biol Cell 7:505, 1996.

24.
Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E: Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene 12:2631, 1996.

25.
Wei P, Garber ME, Fang SM, Fischer WH, Jones KA: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451, 1998.

26.
Peng J, Zhu Y, Milton JT, Price DH: Identification of multiple cyclin subunits of human P-TEFb. Genes Dev 12:755, 1998.

27.
Bagella L, MacLachlan TK, Buono RJ, Pisano MM, Giordano A, De Luca A: Cloning of murine CDK9/PITALRE and its tissue-specific expression in development. J Cell Physiol 177:206, 1998.

28.
Zhou Q, Chen D, Pierstorff E, Luo K: Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. Embo J 17:3681, 1998.

29.
Chen D, Fong Y, Zhou Q: Specific interaction of Tat with the human but not rodent P-TEFb complex mediates the species-specific Tat activation of HIV-1 transcription. Proc Natl Acad Sci U S A 96:2728, 1999.

30.
Napolitano G, Licciardo P, Gallo P, Majello B, Giordano A, Lania L: The CDK9-associated cyclins T1 and T2 exert opposite effects on HIV-1 Tat activity. AIDS 13:1453, 1999.

31.
Hunt T: Cyclins and their partners: from a simple idea to complicated reality. Semin Cell Biol 2:213, 1991.

32.
Lees EM, Harlow E: Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase. Mol Cell Biol 13:1194, 1993.

33.
Wang J, Zindy F, Chenivesse X, Lamas E, Henglein B, Brechot C: Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene 7:1653, 1992.

34.
Dulic V, Lees E, Reed SI: Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257:1958, 1992.

35.
Ohtsubo M, Roberts JM: Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259:1908, 1993.

36.
Verde F, Dogterom M, Stelzer E, Karsenti E, Leibler S: Control of microtubule dynamics and length by cyclin A- and cyclin B- dependent kinases in Xenopus egg extracts. J Cell Biol 118:1097, 1992.

37.
McGowan CH, Russell P, Reed SI: Periodic biosynthesis of the human M-phase promoting factor catalytic subunit p34 during the cell cycle. Mol Cell Biol 10:3847, 1990.

38.
Buendia B, Draetta G, Karsenti E: Regulation of the microtubule nucleating activity of centrosomes in Xenopus egg extracts: role of cyclin A-associated protein kinase. J Cell Biol 116:1431, 1992.

39.
Maldonado-Codina G, Glover DM: Cyclins A and B associate with chromatin and the polar regions of spindles, respectively, and do not undergo complete degradation at anaphase in syncytial Drosophila embryos. J Cell Biol 116:967, 1992.

40.
Gallant P, Nigg EA: Cyclin B2 undergoes cell cycle-dependent nuclear translocation and, when expressed as a non-destructible mutant, causes mitotic arrest in HeLa cells. J Cell Biol 117:213, 1992.

41.
Ookata K, Hisanaga S, Okano T, Tachibana K, Kishimoto T: Relocation and distinct subcellular localization of p34cdc2-cyclin B complex at meiosis reinitiation in starfish oocytes. Embo J 11:1763, 1992.

42.
Fujinaga K, Cujec TP, Peng J, et al: The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J Virol 72:7154, 1998.

43.
Isel C, Karn J: Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation. J Mol Biol 290:929, 1999.

44.
Garriga J, Peng J, Parreno M, Price DH, Henderson EE, Grana X: Upregulation of cyclin T1/CDK9 complexes during T cell activation. Oncogene 17:3093, 1998.

45.
MacLachlan TK, Sang N, De Luca A, Puri PL, Levrero M, Giordano A: Binding of CDK9 to TRAF2. J Cell Biochem 71:467, 1998.

46.
Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707, 1993.

47.
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805, 1993.

48.
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases [see comments]. Nature 366:701, 1993.

49.
Nourse J, Firpo E, Flanagan WM, et al: Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570, 1994.

50.
Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 79:487, 1994.

51.
Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 [see comments]. Nature 366:704, 1993.

52.
Guan KL, Jenkins CW, Li Y, et al: Growth suppression by p18, a p16INK4AINK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type prb function. Genes Dev 8:2939, 1994.

53.
Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A: Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4Aink4. Mol Cell Biol 15:2682, 1995.

54.
Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672, 1995.

55.
Hannon GJ, Beach D: p15INK4BINK4B is a potential effector of Tgf-beta-induced cell cycle arrest [see comments]. Nature 371:257, 1994.

56.
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753, 1994.

57.
Schwob E, Bohm T, Mendenhall MD, Nasmyth K: The B-type cyclin kinase inhibitor p40SIC1 controls the G1 to S transition in S. cerevisiae [published erratum appears in Cell 1996 Jan 12;84(1):following 174]. Cell 79:233, 1994.

58.
Bai C, Sen P, Hofmann K, et al: SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86:263, 1996.

59.
Feldman RM, Correll CC, Kaplan KB, Deshaies RJ: A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p [see comments]. Cell 91:221, 1997.

60.
Skowyra D, Koepp DM, Kamura T, et al: Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1 [see comments]. Science 284:662, 1999.

61.
Koepp DM, Harper JW, Elledge SJ: How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97:431, 1999.

62.
Hunter T, Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age [see comments]. Cell 79:573, 1994.

63.
Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149, 1995.

64.
Zhang H, Xiong Y, Beach D: Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4:897, 1993.

65.
El-Deiry WS, Harper JW, O’Connor PM, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169, 1994.

66.
Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90, 1994.

67.
Li Y, Jenkins CW, Nichols MA, Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261, 1994.

68.
Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675, 1995.

69.
Dirick L, Nasmyth K: Positive feedback in the activation of G1 cyclins in yeast. Nature 351:754, 1991.

70.
Rodrigues GA, Park M: Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol 13:6711, 1993.

71.
Mezzelani A, Alasio L, Bartoli C, et al: c-eRbB2/neu gene and chromosome 17 analysis in breast cancer by Fish on archival cytological fine-needle aspirates. Br J Cancer 80:519, 1999.

72.
Haapasalo H, Hyytinen E, Sallinen P, Helin H, Kallioniemi OP, Isola J: c-eRbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer 73:620, 1996.

73.
Engelhard HH, Wolters M, Criswell PS: Analysis of c-eRbB2 protein content of human glioma cells and tumor tissue. J Neurooncol 23:31, 1995.

74.
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma [published erratum appears in Science 1995 Jan 20;267(5196):316-7]. Science 263:1281, 1994.

75.
Fujimoto J, Shiota M, Iwahara T, et al: Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A 93:4181, 1996.

76.
Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307, 1994.

77.
Mittebauer G, Nemeth P, Wacha S, et al: Quantification of minimal residual disease in patients with BCR-ABL- positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Br J Haematol 106:634, 1999.

78.
Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW: The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow [see comments]. Blood 94:384, 1999.

79.
Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362, 1998.

80.
Hoppener JW, Lips CJ: RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects. Eur J Clin Invest 26:613, 1996.

81.
Galisteo ML, Dikic I, Batzer AG, Langdon WY, Schlessinger J: Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation. J Biol Chem 270:20242, 1995.

82.
Graham SM, Cox AD, Drivas G, et al: Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation. Mol Cell Biol 14:4108, 1994.

83.
Graham SM, Oldham SM, Martin CB, et al: TC21 and Ras share indistinguishable transforming and differentiating activities. Oncogene 18:2107, 1999.

84.
Cox AD, Brtva TR, Lowe DG, Der CJ: R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells. Oncogene 9:3281, 1994.

85.
Saez R, Chan AM, Miki T, Aaronson SA: Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes. Oncogene 9:2977, 1994.

86.
Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ: Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 15:6443, 1995.

87.
Qiu RG, Chen J, Kirn D, McCormick F, Symons M: An essential role for Rac in Ras transformation. Nature 374:457, 1995.

88.
Qiu RG, Chen J, McCormick F, Symons M: A role for Rho in Ras transformation. Proc Natl Acad Sci U S A 92:11781, 1995.

89.
Nobes CD. Hall A: Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81:53, 1995.

90.
Belliveau MJ, Lutchman M, Claudio JO, Marineau C, Rouleau GA: Schwannomin: new insights into this member of the band 4.1 superfamily. Biochem Cell Biol 73:733, 1995.

91.
Turner BC, Harrold E, Matloff E, et al: BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17:301724, 1999.

92.
Neuhausen SL, Ostrander EA: Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2. Genet Test 1:75, 1997.

93.
Yang X, Lippman ME: BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat 54:1, 1999.

94.
Chapman MS, Verma IM: Transcriptional activation by BRCA1 [letter; comment]. Nature 382:678, 1996.

95.
Coso OA, Chiariello M, Yu JC, et al: The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81:1137, 1995.

96.
Minden A, Lin A, Claret FX, Abo A, Karin M: Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81:1147, 1995.

97.
Johnson NL, Gardner AM, Diener KM, et al: Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. J Biol Chem 271:3229, 1996.

98.
Lavoie JN, Rivard N, L’Allemain G, Pouyssegur, J: A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog Cell Cycle Res 2:49, 1996.

99.
Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333, 1994.

100.
Koken MH, Puvion-Dutilleul F, Guillemin MC, et al: The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. Embo J 13:1073, 1994.

101.
Martinelli G, Ottaviani E, Visani G, Testoni N, Montefusco V, Tura S: Long-term disease-free acute promyelocytic leukemia patients really can be cured at molecular level [letter]. Haematologica 83:860, 1998.

102.
Fenaux P, Chomienne C, Degos L: Acute promyelocytic leukemia: biology and treatment. Semin Oncol 24:92, 1997.

103.
Hussey CE, Lyon E, Millson A, Lay MJ, Wittwer CT, Segal GH: A rapid practical RT-PCR-based approach for the detection of the PML/RAR alpha fusion transcript in acute promyelocytic leukemia. Am J Clin Pathol 112:256, 1999.

104.
Chen Z, Brand NJ, Chen A, et al: Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. Embo J 12:1161, 1993.

105.
Monni O, Franssila K, Joensuu H, Knuutila S: BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 34:45, 1999.

106.
Kramer MH, Hermans J, Wijburg E, et al: Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152, 1998.

107.
Kojima K, Taniwaki M, Yoshino T, et al: Trisomy 12 and t(14;18) in B-cell chronic lymphocytic leukemia. Int J Hematol 67:199, 1998.

108.
Bonnotte B, Favre N, Moutet M, et al: Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol 161:1433, 1998.

109.
Yin DX, Schimke RT: Inhibition of apoptosis by overexpressing Bcl-2 enhances gene amplification by a mechanism independent of aphidicolin pretreatment. Proc Natl Acad Sci U S A 93:3394, 1996.

110.
Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG Jr: Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 18:6316, 1998.

111.
Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA: Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18:7185, 1998.

112.
Lutterbach B, Westendorf JJ, Linggi B, et al: ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18:7176, 1998.

113.
Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM: ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 95:10860, 1998.

114.
Wong CW, Privalsky ML: Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARa, and BCL-6. J Biol Chem 273:27695, 1998.

115.
David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A: Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16:2549, 1998.

116.
Dhordain P, Lin RJ, Quief S, et al: The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 26:4645, 1998.

117.
Yunis JJ, Ramsay N: Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child 132:161, 1978.

118.
Grana X, Garriga J, Mayol X: Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 17:3365, 1998.

119.
Bookstein R, Lee WH: Molecular genetics of the retinoblastoma suppressor gene. Crit Rev Oncog 2:211, 1991.

120.
Chellappan S, Kraus VB, Kroger B, et al: Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci U S A 89:4549, 1992.

121.
Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387:296, 1997.

122.
Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 387:299, 1997.

123.
Honda R, Tanaka H, Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25, 1997.

124.
Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ: Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. Embo J 17:554, 1998.

125.
Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of theINK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993, 1995.

126.
Chin L, Pomerantz J, DePinho RA: TheINK4A/ARF tumor suppressor: one gene—two products—two pathways. Trends Biochem Sci 23:291, 1998.

127.
Kamijo T, Zindy F, Roussel MF, et al: Tumor suppression at the mouseINK4A locus mediated by the alternative reading frame product p19ARF. Cell 91:649, 1997.

128.
Bates S, Phillips AC, Clark PA, et al: p14arf links the tumour suppressors Rb and p53 [letter]. Nature 395:124, 1998.

129.
Palmero I, Pantoja C, Serrano M: p19arf links the tumour suppressor p53 to Ras [letter]. Nature 395:125, 1998.

130.
Prives C: Signaling to p53: breaking the MDM2-p53 circuit. Cell 95:5, 1998.

131.
Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Dev 12:2984, 1998.

132.
Prives C, Hall PA: The p53 pathway. J Pathol 187:112, 1999.

133.
Jost CA, Marin MC, Kaelin WG Jr: p73 is a simian [correction of human] p53-related protein that can induce apoptosis [see comments] [published erratum appears in Nature 1999 Jun 24;399(6738):817]. Nature 389:191, 1997.

134.
Di Como CJ, Gaiddon C, Prives C: p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19:1438, 1999.

135.
Kawano S, Miller CW, Gombart AF, et al: Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94:1113, 1999.

136.
Nishikawa R, Furnari FB, Lin H, et al: Loss of P16INK4AINK4 expression is frequent in high grade gliomas. Cancer Res 55:1941, 1995.

137.
Olopade OI, Jenkins RB, Ransom DT, et al: Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 52:2523, 1992.

138.
Okami K, Cairns P, Westra WH, et al: Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. Int J Cancer 74:588, 1997.

139.
Schmid M, Malicki D, Nobori T, et al: Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4AINK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene 17:2669, 1998.

140.
Stadler WM, Olopade OI: The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 24:239, 1996.

141.
Balazs M, Carroll P, Kerschmann R, Sauter G, Waldman FM: Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16INK4A) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 19:84, 1997.

142.
Orlow I, Lacombe L, Hannon GJ, et al: Deletion of the p16INK4A and p15INK4B genes in human bladder tumors [see comments]. J Natl Cancer Inst 87:1524, 1995.

143.
Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ, Coto E: Deletion and methylation of the tumour suppressor gene p16INK4A/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol 50:509, 1997.

144.
Matsuura K, Shiga K, Yokoyama J, Saijo S, Miyagi T, Takasaka T: Loss of heterozygosity of chromosome 9p21 and 7q31 is correlated with high incidence of recurrent tumor in head and neck squamous cell carcinoma. Anticancer Res 18:453, 1998.

145.
Waber P, Dlugosz S, Cheng QC, Truelson J, Nisen PD: Genetic alterations of chromosome band 9p21 in head and neck cancer are not restricted to p16INK4AINK4A. Oncogene 15:1699, 1997.

146.
Yamada Y, Hatta Y, Murata K, et al: Deletions of p15INK4B and/or p16INK4A genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 15:1778, 1997.

147.
Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP: Homozygous deletions of the p15INK4B (MTS2) and p16INK4A (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 85:2699, 1995.

148.
Hori Y, Hori H, Yamada Y, et al: The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4AINK4A gene in acute type adult T-cell leukemia. Int J Cancer 75:51, 1998.

149.
Kratzke RA, Otterson GA, Lincoln CE, et al: Immunohistochemical analysis of the p16INK4AINK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87:1870, 1995.

150.
Cayuela JM, Gardie B, Sigaux F: Disruption of the multiple tumor suppressor gene MTS1/p16INK4A(INK4A)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood 90:3720, 1997.

151.
Jaffrain-Rea ML, Ferretti E, Toniato E, Cannita K, Santoro A, Di Stefano, Ricevuto E, Maroder M, Tamburrano G, Cantore G, Gulino A, Martinotti S: p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. Clin Endocrinol (Oxf) 51(3):317, 1999.

152.
Melki JR, Vincent PC, Clark SJ: Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59:3730, 1999.

153.
Nakamura M, Sugita K, Inukai T, et al: p16INK4A/Mts1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. Leukemia 13:884, 1999.

154.
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141, 1998.

155.
Drexler HG: Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15INK4B, p16INK4A, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845, 1998.

156.
Timmermann S, Hinds PW, Munger K: Re-expression of endogenous p16INK4AINK4A in oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state. Oncogene 17:3445, 1998.

157.
Bender CM, Pao MM, Jones PA: Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58:95, 1998.

158.
Kantarjian HM, O’Brien SM, Keating M, et al: Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11:1617, 1997.

159.
Zagonel V, Lo Re G, Marotta G, et al: 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7(suppl 1):30, 1993.

160.
Petti MC, Mandelli F, Zagonel V, et al: Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 7(suppl 1):36, 1993.

161.
Quesnel B, Guillerm G, Vereecque R, et al: Methylation of the p15INK4B(INK4B) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985, 1998.

162.
Razin A: CpG methylation, chromatin structure and gene silencing—a three-way connection. Embo J 17:4905, 1998.

163.
Jones PL, Veenstra GJ, Wade PA, et al: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187, 1998.

164.
Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M: A mammalian protein with specific demethylase activity for mCpG DNA [see comments]. Nature 397:579, 1999.

165.
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103, 1999.
Books@Ovid
Copyright © 2001 McGraw-Hill
Ernest Beutler, Marshall A. Lichtman, Barry S. Coller, Thomas J. Kipps, and Uri Seligsohn
Williams Hematology

Advertisements

5 comments on “CHAPTER 12 CELL CYCLE REGULATION AND HEMATOLOGICAL DISORDERS

  1. `Thanks for the post. It was really helpful to solve my confusion.

    <a rel="dofollow" href="http://www.sssbpo.com/medical-transcription-company-india.html

  2. […] CHAPTER 12 CELL CYCLE REGULATION AND HEMATOLOGICAL … . to the mammalian cell cycle. One must understand basic cell cycle regulation in order to understand the mechanisms that lead to hematological malignancies and the importance of tumor suppressor genes and oncogenes. […]

  3. Found your weblog and decided to have a study on it, not what I generally do, but this weblog is great. Awesome to see a site that’s not spammed, and in fact makes some sense. Anyway, great write up.

  4. […] #split {}#single {}#splitalign {margin-left: auto; margin-right: auto;}#singlealign {margin-left: auto; margin-right: auto;}#splittitlebox {text-align: center;}#singletitlebox {text-align: center;}.linkboxtext {line-height: 1.4em;}.linkboxcontainer {padding: 7px 7px 7px 7px;background-color:#eeeeee;border-color:#000000;border-width:0px; border-style:solid;}.linkboxdisplay {padding: 7px 7px 7px 7px;}.linkboxdisplay td {text-align: center;}.linkboxdisplay a:link {text-decoration: none;}.linkboxdisplay a:hover {text-decoration: underline;} function opensingledropdown() { document.getElementById('singletablelinks').style.display = ''; document.getElementById('singlemouse').style.display = 'none'; } function closesingledropdown() { document.getElementById('singletablelinks').style.display = 'none'; document.getElementById('singlemouse').style.display = ''; } Navitoclax (ABT-263) Reduces GDC-0941 Ispinesib and XL765 Mediated Chemo-resistance in Ovarian Cancer ModelsHTS for BRCA2 Deficient Tumor Cells, HTSSorafenib: A Multikinase Inhibitor in Compound Libraries, sorafenibMyrexis Presents at 2011 EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics SymposiumChemosensitive Augment and Antitumor Mechanism of Norcantharidin on Multiple Myeloma Masitinib, a canine anti-cancer drug, shows promise in humansJCI online early table of contents: Feb. 6, 2012CHAPTER 12 CELL CYCLE REGULATION AND HEMATOLOGICAL DISORDERS […]

  5. […] The Prevention Of Hereditary Breast And Ovarian Cancer By PGD Is ‘Feasible’CHAPTER 12 CELL CYCLE REGULATION AND HEMATOLOGICAL DISORDERS […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: